Sivia Capital Partners LLC Has $224,000 Holdings in GSK plc (NYSE:GSK)

Sivia Capital Partners LLC raised its stake in GSK plc (NYSE:GSK) by 29.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,610 shares of the pharmaceutical company’s stock after buying an additional 1,507 shares during the period. Sivia Capital Partners LLC’s holdings in GSK were worth $224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Enterprise Bank & Trust Co boosted its position in shares of GSK by 3.0% during the 4th quarter. Enterprise Bank & Trust Co now owns 26,892 shares of the pharmaceutical company’s stock worth $909,000 after purchasing an additional 791 shares in the last quarter. Keystone Financial Planning Inc. boosted its holdings in shares of GSK by 3,660.9% in the 4th quarter. Keystone Financial Planning Inc. now owns 227,913 shares of the pharmaceutical company’s stock worth $7,708,000 after buying an additional 221,853 shares during the last quarter. Thomasville National Bank increased its stake in shares of GSK by 3.4% during the 4th quarter. Thomasville National Bank now owns 491,441 shares of the pharmaceutical company’s stock worth $16,621,000 after purchasing an additional 16,057 shares during the last quarter. Brookstone Capital Management raised its stake in shares of GSK by 19.8% in the fourth quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company’s stock valued at $1,072,000 after buying an additional 5,244 shares during the period. Finally, Fiduciary Alliance LLC purchased a new position in GSK in the 4th quarter valued at approximately $390,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

GSK stock traded down $0.41 during mid-day trading on Monday, reaching $32.68. 3,887,908 shares of the company’s stock traded hands, compared to its average volume of 3,069,380. GSK plc has a 12-month low of $32.55 and a 12-month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock has a 50 day moving average of $34.38 and a two-hundred day moving average of $38.17. The company has a market cap of $67.73 billion, a price-to-earnings ratio of 21.22, a PEG ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date was Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.81%. GSK’s dividend payout ratio is 95.45%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Monday. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.